

RECEIVED
CENTRAL FAX CENTER

001

JUN 28 2005

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO: Examiner: Evelyn Huang
USPTO

FAX NUMBER:
(703) 872-9306

FROM: Palaiyur S. Kalyanaraman

PHONE NUMBER:
(908) 298-5068

TOTAL NO. OF PAGES INCLUDING COVER
17

DATE
June 28, 2005

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:


PLEASE HAND DELIVER

In re Application of: Michael P. Dwyer *et al.*
For Patent entitled: "Novel Imidazopyridines as Cyclin Dependent Kinase Inhibitors"
Group Art Unit: 1625
Filed: 09/17/2003
Attorney Docket No.: OC01628K
Serial No.: 10/664,338

Dear Examiner Huang,

Transmitted herewith are:

- Fax Cover Sheet – 1pg.
- Certificate of Transmission – 1pg.
- Response Transmittal – 1pg.
- Response – 14 pages


Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

RECEIVED
CENTRAL FAX CENTER
JUN 28 2005

Docket Number: OC01628K
Application No: 10/664,338
Filing Date: 09/17/2003
First Inventor: DWYER, Michael P.

PTO/SB/97 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on 06/28/2005
Date


Signature

Palaiyur S. Kalyanaraman

Typed or printed name of person signing Certificate

34,634 (908) 298-5068
Registration Number, if applicable Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fax Cover Sheet - 1pg.
Certificate of Transmission - 1pg.
Response Transmittal - 1pg.
Response - 14pgs.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/664,338	
	Filing Date	09/17/2003	
	First Named Inventor	DWYER, Michael P.	
	Art Unit	1625	
	Examiner Name	Evelyn Huang	
Total Number of Pages In This Submission	17	Attorney Docket Number	OC01628K

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Fax Cover Sheet - 1pg.
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name			
Signature			
Printed name	PALAIYUR S. KALYANARAMAN		
Date	06/28/2005	Reg. No.	84,534

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Palaiyur S. Kalyanaraman	Date	06/28/2005

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT: OC01628K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 In re Application of

Michael P. Dwyer et al.

10 Appln. No.: 10/664,338

Conf. No.: 4130

Filed: September 17, 2003

15 For: "Novel Imidazopyridines as Cyclin
Dependent Kinase Inhibitors"

Examiner: Evelyn Huang

Group Art Unit: 1625

Date: June 28, 2005

20 Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

25 RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT
AMENDMENT AFTER FINAL REJECTION PER 37 C.F.R § 1.116

This communication is in response to the Notice of Non-compliant Amendment that the Examiner issued on May 11, 2005, in the above-identified patent application, which followed Applicants' Amendment after Final Rejection filed on April 27, 2005. Claims 1-19, 29 and 31 are pending in this case. Applicants respectfully request entry and consideration of this Response to the Non-compliant amendment. Since this Response is being filed within three months of the date of the Final Rejection, no fee is believed due. This Response is being faxed to the Examiner's attention at 703-872-9306.

35 **Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 15 of this paper.